Similarly, Bonora et al. determined that after 12 weeks of treatment with dapagliflozin, the number of circulating stem cells CSC (CD34+) and EPCs (CD34+KDR+) were slightly reduced in T2DM patients, while the same duration treatment with empagliflozin diminished the CSC levels in a non-significant way [197]. This evidence concerns the gene CD34 and type 2 diabetes mellitus.